Neumora Therapeutics IPO Presentation Deck

Navacaprant: Established Proof-of-Concept for Treatment of Depression and Anhedonia in Patients with Moderate-to-Severe MDD Change From Baseline HAMD-17, LS Mean (SE) 0 -2 CO -10 -12 Week 0 HAMD-17 Week 4 -5.5 -8.5 ALSM = -3.0 P = 0.015 Week 8 -7.1 -9.9 ALSM = -2.8 P = 0.037 Improvement Change From Baseline SHAPS, LS Mean (SE) - Placebo - Navacaprant Note: Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 > 22) 0 -2 -4 6 -8 -10 -12 Week 0 SHAPS Week 4 -4.0 -6.4 ALSM = -2.4 P = 0.071 Week 8 -4.4 -9.2 ALSM = -4.8 P = 0.0006 Improvement Confidential 10

View entire presentation